ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Arkansas » Hematology Oncology

Top Hematology Oncology Prescribers in Arkansas

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
MIRFAT BIRD M.D.

Hematology Oncology

14,045

$1.08M

345
223 are 65+

19%
patients receiving schedule two controlled substances

Avg: 18%

43%
patients receiving schedule three controlled substances

Avg: 16%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

23%
prescriptions for brand name drugs

Avg: 17%

$77
Average prescription price

Avg: $391

THOMAS SNEED M.D.

Hematology Oncology

4,638

$1.16M

489
382 are 65+

16%
patients receiving schedule two controlled substances

Avg: 18%

22%
patients receiving schedule three controlled substances

Avg: 16%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

14%
prescriptions for brand name drugs

Avg: 17%

$249
Average prescription price

Avg: $391

BART BARLOGIE MD

Hematology Oncology

3,954

$7.52M

421
294 are 65+

14%
patients receiving schedule two controlled substances

Avg: 18%

6%
patients receiving schedule three controlled substances

Avg: 16%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

39%
prescriptions for brand name drugs

Avg: 17%

$1902
Average prescription price

Avg: $391

PATRICK TRAVIS M.D.

Hematology Oncology

3,125

$784K

271
194 are 65+

28%
patients receiving schedule two controlled substances

Avg: 18%

20%
patients receiving schedule three controlled substances

Avg: 16%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

19%
prescriptions for brand name drugs

Avg: 17%

$251
Average prescription price

Avg: $391

MARIANN HARRINGTON M.D.

Hematology Oncology

3,029

$650K

310
248 are 65+

9%
patients receiving schedule two controlled substances

Avg: 18%

18%
patients receiving schedule three controlled substances

Avg: 16%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

14%
prescriptions for brand name drugs

Avg: 17%

$215
Average prescription price

Avg: $391

LAWRENCE MENDELSOHN MD

Hematology Oncology

2,985

$1.05M

371
300 are 65+

8%
patients receiving schedule two controlled substances

Avg: 18%

13%
patients receiving schedule three controlled substances

Avg: 16%

7%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

21%
prescriptions for brand name drugs

Avg: 17%

$350
Average prescription price

Avg: $391

BALAGOPALAN NAIR M.D.

Hematology Oncology

2,891

$1.18M

379
292 are 65+

14%
patients receiving schedule two controlled substances

Avg: 18%

15%
patients receiving schedule three controlled substances

Avg: 16%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

15%
prescriptions for brand name drugs

Avg: 17%

$407
Average prescription price

Avg: $391

VARANT ARZOUMANIAN MD

Hematology Oncology

2,543

$1.04M

296
213 are 65+

20%
patients receiving schedule two controlled substances

Avg: 18%

14%
patients receiving schedule three controlled substances

Avg: 16%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

17%
prescriptions for brand name drugs

Avg: 17%

$408
Average prescription price

Avg: $391

DIANE WILDER M.D.

Hematology Oncology

2,450

$199K

291
223 are 65+

9%
patients receiving schedule two controlled substances

Avg: 18%

11%
patients receiving schedule three controlled substances

Avg: 16%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

9%
prescriptions for brand name drugs

Avg: 17%

$81
Average prescription price

Avg: $391

TONY FLIPPIN MD

Hematology Oncology

2,440

$292K

238
198 are 65+

12%
patients receiving schedule two controlled substances

Avg: 18%

25%
patients receiving schedule three controlled substances

Avg: 16%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

14%
prescriptions for brand name drugs

Avg: 17%

$120
Average prescription price

Avg: $391

STEPHEN DIVERS M.D.

Hematology Oncology

2,414

$1.12M

279
235 are 65+

13%
patients receiving schedule two controlled substances

Avg: 18%

20%
patients receiving schedule three controlled substances

Avg: 16%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

19%
prescriptions for brand name drugs

Avg: 17%

$466
Average prescription price

Avg: $391

GREGORY OAKHILL M.D.

Hematology Oncology

2,386

$801K

267
201 are 65+

29%
patients receiving schedule two controlled substances

Avg: 18%

27%
patients receiving schedule three controlled substances

Avg: 16%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

17%
prescriptions for brand name drugs

Avg: 17%

$336
Average prescription price

Avg: $391

J BECK M.D., F.A.C.P.

Hematology Oncology

2,211

$628K

272
202 are 65+

26%
patients receiving schedule two controlled substances

Avg: 18%

11%
patients receiving schedule three controlled substances

Avg: 16%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

15%
prescriptions for brand name drugs

Avg: 17%

$284
Average prescription price

Avg: $391

KAMAL PATEL M.D.

Hematology Oncology

2,038

$1.25M

245
179 are 65+

10%
patients receiving schedule two controlled substances

Avg: 18%

9%
patients receiving schedule three controlled substances

Avg: 16%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

26%
prescriptions for brand name drugs

Avg: 17%

$612
Average prescription price

Avg: $391

FRITS VAN RHEE MD

Hematology Oncology

2,021

$2.28M

214
134 are 65+

21%
patients receiving schedule two controlled substances

Avg: 18%

8%
patients receiving schedule three controlled substances

Avg: 16%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

30%
prescriptions for brand name drugs

Avg: 17%

$1129
Average prescription price

Avg: $391

ROY WEBB M.D.

Hematology Oncology

2,009

$840K

248
207 are 65+

11%
patients receiving schedule two controlled substances

Avg: 18%

22%
patients receiving schedule three controlled substances

Avg: 16%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

20%
prescriptions for brand name drugs

Avg: 17%

$418
Average prescription price

Avg: $391

DANIEL BRADFORD M.D.

Hematology Oncology

1,981

$638K

253
196 are 65+

26%
patients receiving schedule two controlled substances

Avg: 18%

17%
patients receiving schedule three controlled substances

Avg: 16%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

18%
prescriptions for brand name drugs

Avg: 17%

$322
Average prescription price

Avg: $391

STEPHAN ROSENFELD M.D.

Hematology Oncology

1,791

$369K

313
251 are 65+

23%
patients receiving schedule two controlled substances

Avg: 18%

9%
patients receiving schedule three controlled substances

Avg: 16%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

8%
prescriptions for brand name drugs

Avg: 17%

$206
Average prescription price

Avg: $391

DANIEL MACKEY MD

Hematology Oncology

1,740

$759K

207
161 are 65+

18%
patients receiving schedule two controlled substances

Avg: 18%

15%
patients receiving schedule three controlled substances

Avg: 16%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

19%
prescriptions for brand name drugs

Avg: 17%

$436
Average prescription price

Avg: $391

MAZEN KHALIL M.D.

Hematology Oncology

1,613

$741K

233
168 are 65+

18%
patients receiving schedule two controlled substances

Avg: 18%

22%
patients receiving schedule three controlled substances

Avg: 16%

7%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

15%
prescriptions for brand name drugs

Avg: 17%

$459
Average prescription price

Avg: $391

ERIC SCHAEFER M.D.

Hematology Oncology

1,577

$609K

205
145 are 65+

31%
patients receiving schedule two controlled substances

Avg: 18%

20%
patients receiving schedule three controlled substances

Avg: 16%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

16%
prescriptions for brand name drugs

Avg: 17%

$386
Average prescription price

Avg: $391

BIJAY NAIR MD

Hematology Oncology

1,490

$897K

181
122 are 65+

16%
patients receiving schedule two controlled substances

Avg: 18%

0%
patients receiving schedule three controlled substances

Avg: 16%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

27%
prescriptions for brand name drugs

Avg: 17%

$602
Average prescription price

Avg: $391

KEWEN JAUSS M.D.

Hematology Oncology

1,400

$409K

164
138 are 65+

16%
patients receiving schedule two controlled substances

Avg: 18%

21%
patients receiving schedule three controlled substances

Avg: 16%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

19%
prescriptions for brand name drugs

Avg: 17%

$292
Average prescription price

Avg: $391

ROBERT MULDOON M.D.

Hematology Oncology

1,317

$653K

150
120 are 65+

15%
patients receiving schedule two controlled substances

Avg: 18%

24%
patients receiving schedule three controlled substances

Avg: 16%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

19%
prescriptions for brand name drugs

Avg: 17%

$496
Average prescription price

Avg: $391

NARENDER GORUKANTI MD

Hematology Oncology

1,155

$206K

157
135 are 65+

14%
patients receiving schedule two controlled substances

Avg: 18%

17%
patients receiving schedule three controlled substances

Avg: 16%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 3%

12%
prescriptions for brand name drugs

Avg: 17%

$179
Average prescription price

Avg: $391

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank